Jenburkt Pharmaceuticals Limited held its 41st Annual General Meeting (AGM) on Friday, 4th September, 2026, from 3:30 PM to 4:50 PM IST through Video Conferencing/Other Audio-Visual Means (VC/OAVM). The meeting was conducted in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulations 30 and Clause 13 Para A of Part A of Schedule III.

The meeting commenced at 3:30 PM IST with requisite quorum present throughout as required under Section 103 of the Companies Act, 2013. The Chairman welcomed members and the Senior Vice President and Company Secretary provided statutory information about the meeting arrangements.

Remote e-voting facilities were provided through National Securities Depository Limited (NSDL) from 9:00 AM on 1st September 2026 to 5:00 PM on 3rd September 2026. Members present at the AGM who had not voted remotely were given an opportunity to vote during the meeting and for 15 minutes after its conclusion.

M/s. Nilesh Shah & Associates, Practicing Company Secretaries, were appointed as scrutinizer to ensure fair and transparent e-voting process. Directors, statutory auditors, secretarial auditors, and the scrutinizer joined the meeting from various locations through VC/OAVM.

The Notice of AGM, financial statements for FY 2025-26, Directors' Report, and Auditors' Reports were taken as read. It was confirmed that both Statutory Auditors' Report and Secretarial Auditor's Report contained no adverse qualifications, reservations, adverse remarks, or disclaimers.

The Chairman highlighted the company's performance including growth in revenue and profitability, debt-free and cash-rich position, product innovations, market presence strengthening, scientific engagements, human resource initiatives, and digital transformation. The company's Patient-First philosophy and commitment to ethical business practices and social responsibility were emphasized.

All 46 shareholder questions were addressed, covering topics including financial results, products, buy-back, field staff, future projects, and domestic/international markets.

Resolutions Voted On

Five resolutions were put to vote through remote e-voting and e-voting at the meeting:

Ordinary Business:

  • Resolution 1: Adoption of audited financial statements for FY ended 31st March 2026, together with Board of Directors' and Auditors' reports (Ordinary Resolution)
  • Resolution 2: Declaration of dividend of ₹20.70 (207%) per equity share of ₹10 each for FY ended 31st March 2026 (Ordinary Resolution)
  • Resolution 3: Appointment of director in place of Shri Dilip H. Bhuta (DIN: 03157252) who retires by rotation and offers himself for reappointment (Ordinary Resolution)

Special Business:

  • Resolution 4: Reappointment of Shri Dilip H. Bhuta (DIN: 03157252) as Whole Time Director and Chief Financial Officer (CFO) (Special Resolution)
  • Resolution 5: Ratification of remuneration payable to Cost Auditor for FY 2026-27 (Ordinary Resolution)

The consolidated results of remote e-voting and e-voting were to be disseminated to stock exchanges and made available on the company's website (www.jenburkt.com) and NSDL's website (www.evoting@nsdl.com) within two working days from meeting conclusion.

The voting results pursuant to Regulation 44(3) of SEBI LODR Regulations and Report of the Scrutinizer pursuant to Section 108 of Companies Act, 2013 and Rule 20 of Companies (Management and Administration) Rules, 2014 will be submitted in due course.